価格表

在庫・価格 : 2024年05月02日 06時50分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
EpiQuik Circulating Cell-Free DNA Isolation Kit(50samples)
データシート
P-1064-50 EPGエピジェンテックグループ
Epigentek Group Inc.
1 kit ¥59,000
(未発注)
追加

在庫・価格 : 2024年05月02日 06時50分 現在

EpiQuik Circulating Cell-Free DNA Isolation Kit(50samples)

  • 商品コード:P-1064-50
  • メーカー:EPG
  • 包装:1kit
  • 価格: ¥59,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Strotman LN et al. Liquid Biopsies in Oncology and the Current Regulatory Landscape. Mol Diagn Ther 2016 Oct;20(5):429-36
Strotman LN et al
2016/01/01
PubMed
2 Yoshizaki A et al. Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Ann Rheum Dis 2016 10;75(10):1858-65
Yoshizaki A et al
2016/01/01
PubMed
3 Whale AS et al. Control Materials and Digital PCR Methods for Evaluation of Circulating Cell-Free DNA Extractions from Plasma. Methods Mol. Biol. 2018;1768:45-65
Whale AS et al
2018/01/01
PubMed
4 Trigg RM et al. Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. Heliyon 2018 Jul;4(7):e00699
Trigg RM et al
2018/01/01
PubMed
5 Fettke H et al. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 2019 Feb;42(1):13-28
Fettke H et al
2019/01/01
PubMed
6 Martignano F. Cell-Free DNA: An Overview of Sample Types and Isolation Procedures. Methods Mol. Biol. 2019;1909:13-27
Martignano F
2019/01/01
PubMed
7 Deans ZC et al. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Virchows Arch. 2019 Jun;474(6):681-689
Deans ZC et al
2019/01/01
PubMed
8 Thakral D et al. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet? Am J Blood Res 2020;10(3):26-45
Thakral D et al
2020/01/01
PubMed
9 Fang Y., et al., The Standardization Process of cfDNA Research: A New Molecular Marker., Journal of Clinical Cancer Research., 1(2):44204

PubMed
10 M. Castiglia., et al., Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs., Liquid Biopsy in Cancer Patients., CCPATH():55-60

PubMed
  • No.: 1
  • 文献情報:
    Strotman LN et al. Liquid Biopsies in Oncology and the Current Regulatory Landscape. Mol Diagn Ther 2016 Oct;20(5):429-36
    Strotman LN et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Yoshizaki A et al. Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Ann Rheum Dis 2016 10;75(10):1858-65
    Yoshizaki A et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Whale AS et al. Control Materials and Digital PCR Methods for Evaluation of Circulating Cell-Free DNA Extractions from Plasma. Methods Mol. Biol. 2018;1768:45-65
    Whale AS et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Trigg RM et al. Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. Heliyon 2018 Jul;4(7):e00699
    Trigg RM et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Fettke H et al. Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 2019 Feb;42(1):13-28
    Fettke H et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Martignano F. Cell-Free DNA: An Overview of Sample Types and Isolation Procedures. Methods Mol. Biol. 2019;1909:13-27
    Martignano F
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Deans ZC et al. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Virchows Arch. 2019 Jun;474(6):681-689
    Deans ZC et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Thakral D et al. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet? Am J Blood Res 2020;10(3):26-45
    Thakral D et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Fang Y., et al., The Standardization Process of cfDNA Research: A New Molecular Marker., Journal of Clinical Cancer Research., 1(2):44204

  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    M. Castiglia., et al., Technical Aspects for the Evaluation of Circulating Nucleic Acids (CNAs): Circulating Tumor DNA (ctDNA) and Circulating MicroRNAs., Liquid Biopsy in Cancer Patients., CCPATH():55-60

  • 備考:
  • 参照:
    PubMed